Lars Andreas Akslen
Professor, Leder for CCBIO
- E-postLars.Akslen@uib.no
- Telefon+47 55 97 31 82
- BesøksadressePatologisk avdeling, Sentralblokka 2 etg., Haukeland Universitetssjukehus (HUS)evt. CCBIO, Sentralblokka 2 etg., HUS
- PostadressePostboks 78045020 Bergen
Akslen er en sertifisert spesialist i kirurgisk patologi og leder forskningsgruppen Tumor Biology Research Group (etablert i 1995) ved Klinisk Institutt 1, Universitetet i Bergen. Siden 2013 har Akslen vært senterleder for Centre for Cancer Biomarkers CCBIO. Akslens gruppe og CCBIO arbeider med translasjonell kreftforskning med fokus på nye kreftmarkører og målrettet behandling og særlig mekanismer knyttet til hvordan kreftceller påvirkes av mikromiljøet i svulstene, og den betydning dette har for kreftspredning og dårlig prognose. Gruppen har prosjekter på ulike kreftformer, som brystkreft, ondartet melanom, prostatakreft og gynekologisk kreft. Gruppen kombinerer studier av humane tumorprøver med eksperimentelle celle- og dyremodeller. Det overordnede målet er å finne nye biomarkører som kan hjelpe oss til å forutse hvordan aggressive svulster vil utvikle seg og dermed bedre kunne skreddersy behandling.
Vitenskapelig artikkel
- (2014). Nestin expression is associated with aggressive cutaneous melanoma of the nodular type. Modern Pathology. 396-401.
- (2014). Molecular determinants of outcome with mammalian target of rapamycin inhibition in endometrial cancer. Cancer. 603-610.
- (2014). Landscape of genomic alterations in cervical carcinomas. Nature. 371-375.
- (2014). Increased microvascular proliferation is negatively correlated to tumour blood flow and is associated with unfavourable outcome in endometrial carcinomas. British Journal of Cancer. 107-114.
- (2014). GRK3 is essential for metastatic cells and promotes prostate tumor progression. Proceedings of the National Academy of Sciences of the United States of America. 1521-1526.
- (2014). A positive real-time elastography is an independent marker for detection of high-risk prostate cancers in the primary biopsy setting. BJU International. E90-E97.
- (2013). Vascular proliferation is associated with survival in pancreatic ductal adenocarcinoma. APMIS - Journal of Pathologiy, Microbiology and Immunology. 1037-1046.
- (2013). Variation in inflammatory cytokine/growth-factor genes and mammographic density in premenopausal women aged 50-55. PLOS ONE. 8 sider.
- (2013). Outcome after surgery for primary hyperaldosteronism may depend on KCNJ5 tumor mutation status: a population-based study from Western Norway. Langenbeck's Archives of Surgery. 869-874.
- (2013). Molecular subtypes, histopathological grade and survival in a historic cohort of breast cancer patients. Breast Cancer Research and Treatment. 463-473.
- (2013). Melanoma prone families with CDK4 germline mutation: phenotypic profile and associations with MC1R variants. Journal of Medical Genetics. 264-U82.
- (2013). Lack of estrogen receptor-alpha is associated with epithelial-mesenchymal transition and PI3K alterations in endometrial carcinoma. Clinical Cancer Research. 1094-1105.
- (2013). Integrated genomic analysis of the 8q24 amplification in endometrial cancers identifies ATAD2 as essential to MYC-dependent cancers. PLOS ONE. 9 sider.
- (2013). Hormone receptor loss in endometrial carcinoma curettage predicts lymph node metastasis and poor outcome in prospective multicentre trial. European Journal of Cancer. 3431-3441.
- (2013). High-throughput interrogation of PIK3CA, PTEN, KRAS, FBXW7 and TP53 mutations in primary endometrial carcinoma. Gynecologic Oncology. 327-334.
- (2013). Expression of thyroid transcription factor-1 is associated with a basal-like phenotype in breast carcinomas. Diagnostic Pathology.
- (2013). Endothelial microvascular networks affect gene-expression profiles and osteogenic potential of tissue-engineered constructs. Stem Cell Research & Therapy. 10 sider.
- (2013). Dynamic contrast-enhanced MRI in endometrial carcinoma identifies patients at increased risk of recurrence. European Radiology. 2916-2925.
- (2013). Bone marrow-derived Gr1(+) cells can generate a metastasis-resistant microenvironment via induced secretion of thrombospondin-1. Cancer Discovery. 578-589.
- (2013). Analysis of Latvian familial melanoma patients shows novel variants in the noncoding regions of CDKN2A and that the CDK4 mutation R24H is a founder mutation. Melanoma research. 221-226.
- (2013). A variant in FTO shows association with melanoma risk not due to BMI. Nature Genetics. 428-432.
- (2012). Polymorphisms in hormone metabolism and growth factor genes and mammographic density in Norwegian postmenopausal hormone therapy users and non-users. Breast Cancer Research.
- (2012). Microvessel proliferation by co-expression of endothelial nestin and Ki-67 is associated with a basal-like phenotype and aggressive features in breast cancer. Breast. 1-7.
- (2012). Combination of real-time elastography and urine prostate cancer gene 3 (PCA3) detects more than 97 % of significant prostate cancers. Scandinavian Journal of Urology and Nephrology. 211-216.
- (2011). Stathmin Overexpression Identifies High-Risk Patients and Lymph Node Metastasis in Endometrial Cancer. Clinical Cancer Research. 3368-3377.
- (2011). Reprogramming of cell junction modules during stepwise epithelial to mesenchymal transition and accumulation of malignant features in vitro in a prostate cell model. Experimental Cell Research. 234-247.
- (2011). High BMI is significantly associated with positive progesterone receptor status and clinico-pathological markers for non-aggressive disease in endometrial cancer. British Journal of Cancer. 921-926.
- (2011). Glomeruloid microvascular proliferation is associated with lack of response to chemotherapy in breast cancer. British Journal of Cancer. 9-12.
- (2011). Efficient in vivo vascularization of tissue-engineering scaffolds. Journal of Tissue Engineering and Regenerative Medicine. E52-E62.
- (2010). Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. PLoS Medicine. 12 sider.
- (2010). Ki-67 expression is superior to mitotic count and novel proliferation markers PHH3, MCM4 and mitosin as a prognostic factor in thick cutaneous melanoma. BMC Cancer. 15 sider.
- (2010). Expression of aldehyde dehydrogenase a (ALDH1) is associated with basal-like markers and features of aggressive tumors in African breast cancer. British Journal of Cancer. 369-375.
- (2010). Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival. Proceedings of the National Academy of Sciences of the United States of America. 1124-1129.
- (2009). Triple-Negative Breast Cancer: Distinguishing between Basal and Nonbasal Subtypes. Clinical Cancer Research. 2302-2310.
- (2009). TMPRSS2:ERG fusion transcripts in urine from prostate cancer patients correlate with a less favorable prognosis. APMIS - Journal of Pathologiy, Microbiology and Immunology. 575-582.
- (2009). Secondary breast cancer: a 5-year population-based study with review of the literature. APMIS - Journal of Pathologiy, Microbiology and Immunology. 762-767.
- (2009). Prosaposin inhibits tumor metastasis via paracrine and endocrine stimulation of stromal p53 and Tsp-1. Proceedings of the National Academy of Sciences of the United States of America. 12115-12120.
- (2009). Proliferation of immature tumor vessels is a novel marker of clinical progression in prostate cancer. Cancer Research. 4708-4715.
- (2009). Inverse correlation between PDGFC expression and lymphocyte infiltration in human papillary thyroid carcinomas. BMC Cancer. 425.
- (2009). Integrated Genome-Wide DNA Copy Number and Expression Analysis Identifies Distinct Mechanisms of Primary Chemoresistance in Ovarian Carcinomas. Clinical Cancer Research. 1417-1427.
- (2009). Importance of tumour cell invasion in blood and lymphatic vasculature among patients with endometrial carcinoma. Histopathology. 174-183.
- (2009). Identification of a CDK4 R24H mutation-positive melanoma family by analysis of early-onset melanoma patients in Latvia. Melanoma research. 119-122.
- (2009). Hyperoxic treatment induces mesenchymal to epithelial transition in a rat adenocarcinoma model. PLOS ONE.
- (2009). Expression of epidermal growth factor receptor in relation to BRCA1 status, basal-like markers and prognosis in breast cancer. Journal of Clinical Pathology. 139-146.
- (2009). Expression of EZH2 and Ki-67 in colorectal cancer and associations with treatment response and prognosis. British Journal of Cancer. 1282-1289.
- (2009). Deoxyribonucleic acid ploidy in endometrial carcinoma: a reproducible and valid prognostic marker in a routine diagnostic setting. American Journal of Obstetrics and Gynecology. 603-607.
- (2009). Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance. Clinical Cancer Research. 3484-3494.
- (2008). WDR19 expression is increased in prostate cancer compared with normal cells, but low-intensity expression in cancers is associated with shorter time to biochemical failures and local recurrence. Clinical Cancer Research. 1397-1406.
- (2008). Tumor necrosis is associated with increased alphavbeta3 integrin expression and poor prognosis in nodular cutaneous melanomas. BMC Cancer. 362-372.
- (2008). Mutation analysis of the EGFR-NRAS-BRAF pathway in melanomas from black Africans and other subgroups of cutaneous melanoma. Melanoma research. 29-35.
- (2008). Low BMI-1 expression is associated with an activated BMI-1-driven signature, vascular invasion, and hormone receptor loss in endometrial carcinoma. British Journal of Cancer. 1662-1669.
- (2008). Loss of BMI-1 expression is associated with clinical progress of malignant melanoma. Modern Pathology. 583-590.
- (2008). Hyperthermia improves the antitumour effect of metronomic cyclophosphamide in a rat transplantable brain tumour. Radiotherapy and Oncology. 435-442.
- (2008). GATA3 expression in estrogen receptor alpha-negative endometrial carcinomas identifies aggressive tumors with high proliferation and poor patient survival. American Journal of Obstetrics and Gynecology. e 1-7.
- (2008). Expression of EGFR and c-kit is associated with the basal-like phenotype in breast carcinomas of African women. APMIS - Journal of Pathologiy, Microbiology and Immunology. 515-525.
- (2008). Epithelial to Mesenchymal Transition of a Primary Prostate Cell Line with Switches of Cell Adhesion Modules but without Malignant Transformation. PLOS ONE.
- (2008). Drug-sensitive FGFR2 mutations in endometrial carcinoma. Proceedings of the National Academy of Sciences of the United States of America. 8713-8717.
- (2007). Frequency of the basal-like phenotype in African breast cancer. APMIS - Journal of Pathologiy, Microbiology and Immunology. 1391-1399.
- (2007). A Switch from E-Cadherin to N-Cadherin Expression Indicates Epithelial to Mesenchymal Transition and Is of Strong and Independent Importance for the Progress of Prostate Cancer. Clinical Cancer Research. 7003-7011.
- (2006). Role of angiogenesis in human tumor dormancy - Animal models of the angiogenic switch. Cell Cycle. 1779-1787.
- (2006). Pathologic expression of p53 or p16 in preoperative curettage specimens identifies high-risk endometrial carcinomas. American Journal of Obstetrics and Gynecology. 979-986.
- (2006). Is preoperative serum prostate-specific antigen level significantly related to clinical recurrence after radical 14 retropubic prostatectomy for localized prostate cancer? BJU International. 51-55.
- (2006). Gene expression profiles do not consistently predict the clinical treatment response in locally advanced breast cancer. Molecular Cancer Therapeutics. 2914-2918.
- (2006). Gene expression in poorly differentiated papillary thyroid carcinomas. Thyroid. 161-175.
- (2006). Expression of enhancer of zeste homologue 2 is significantly associated with increased tumor cell proliferation and is a marker of aggressive breast cancer. Clinical Cancer Research. 1168-1174.
- (2006). Expression of bFGF/FGFR-1 and vascular proliferation related to clinicopathologic features and tumor progress in localized prostate cancer. Virchows Archiv. 68-74.
- (2006). EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. Journal of Clinical Oncology. 268-273.
- (2006). Body size and thyroid cancer in two million Norwegian men and women. British Journal of Cancer. 366-370.
- (2006). A model of human tumor dormancy: An angiogenic switch from the nonangiogenic phenotype. Journal of the National Cancer Institute. 316-325.
- (2005). Strong expression of ID1 protein is associated with decreased survival, increased expression of ephrin-A1/EPHA2, and reduced thrombospondin-1 in malignant melanoma. British Journal of Cancer. 933-938.
- (2005). Predictors of prostate cancer evaluated by receiver operating characteristics partial area index: a prospective institutional study. Journal of Urology. 425-428.
- (2005). Low frequency of BRAF and CDKN2A mutations in endometrial cancer. International Journal of Cancer. 930-934.
- (2005). Importance of P-cadherin, beta-catenin, and Wnt5a/frizzled for progression of melanocytic tumors and prognosis in cutaneous melanoma. Clinical Cancer Research. 8606-8614.
- (2005). Gene expression profiles in prostate cancer: Association with patient subgroups and tumour differentiation. International Journal of Oncology. 329-336.
- (2005). Early detection of brest cancer based on gene-expression patterns in peripheral blood cells. Breast Cancer Research. R634-R644.
- (2005). BRAF and NRAS mutations are frequent in nodular melanoma but are not associated with tumor cell proliferation or patient survival. Journal of Investigative Dermatology. 312-317.
- (2005). A large Norwegian family with inherited malignant melanoma, multiple atypical nevi, and CDK4 mutation. Genes, Chromosomes and Cancer. 10-18.
- (2004). The prognostic implication of the basal-like (cyclin E-high/p27(low)/p53(+)/glomeruloid-microvascular-proliferation(+)) phenotype of BRCA1-related breast cancer. Cancer Research. 830-835.
- (2004). Significance of PTEN alterations in endometrial carcinoma: a population-based study of mutations, promoter methylation and PTEN protein expression. International Journal of Oncology. 1615-1623.
- (2004). Prognostic impact of histological grade and vascular invasion compared with tumor cell proliferation in endometrial carcinoma of endometrioid type. Histopathology. 472-479.
- (2004). Prognostic impact of alterations in P-cadherin expression and related cell adhesion markers in endometrial cancer. Journal of Clinical Oncology. 1242-1252.
- (2004). Molecular differences between RER+ and RER- sporadic endometrial carcinomas in a large population-based series. International Journal of Gynecological Cancer. 957-965.
- (2004). Karnydanning og tumorkar som mål for kreftterapi. Tidsskrift for Den norske legeforening. 1919-1922.
- (2004). Immunohistochemical and Clinical Characterization of the Basal-like Subtype of Invasive Breast Carcinoma. Clinical Cancer Research. 5367-5374.
- (2004). Altered expression of cell cycle regulators Cyclin D1, p14, p16, CDK4 and Rb in nodular melanomas. International Journal of Oncology. 1559-1565.
- (2003). TP53 gene mutations predict the response to neoadjuvant treatment with 5-fluorouracil and mitomycin in locally advanced breast cancer. Clinical Cancer Research. 5582-5588.
- (2003). Significance of CD 105 expression for tumour angiogenesis and prognosis in endometrial carcinomas. APMIS - Journal of Pathologiy, Microbiology and Immunology. 1011-1018.
- (2003). Predictive value of tumour cell proliferation in locally advanced breast cancer treated with neoadjuvant chemotherapy. European Journal of Cancer. 438-446.
- (2003). Molecular assessment of depth of myometrial invasion in stage I endometrial cancer: a model based on K-ras mutation analysis. Gynecologic Oncology. 218-25.
- (2003). MSI-low, a real phenomenon which varies in frequency among cancer types. Journal of Pathology. 389-94.
- (2003). Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. Journal of the National Cancer Institute. 1482-85.
- (2003). Combined loss of PTEN and p27 expression is associated with tumor cell proliferation by Ki-67 and increased risk of recurrent disease in localized prostate cancer. Clinical Cancer Research. 1474-1479.
- (2003). Benign growth of different prostate zones in aging men with slightly elevated PSA in whom prostate cancer has been excluded: a prospective study of 510 patients. Urology. 447-450.
- (2002). Molecular pathogenesis and prognostic factors in endometrial carcinoma. APMIS - Journal of Pathologiy, Microbiology and Immunology. 673-689.
- (2002). Loss of hMSH2 and hMSH6 expression is frequent in sporadic endometrial carcinomas with microsatellite instability: a population-based study. Clinical Cancer Research. 138-43.
- (2002). Loss of PTEN expression is associated with metastatic disease in patients with endometrial carcinoma. Cancer. 2185-91.
- (2002). Can we rely on pathologic parameters to define conservative treatment of papillary thyroid carcinoma? International Journal of Surgical Pathology. 267-272.
- (2001). Maximum Ki-67 staining in prostate cancer provides independent prognostic information after radical prostatectomy. Anticancer Research. 7 sider.
- (2001). Familial occurrence of nonmedullary thyroid cancer: a population-based study of 5673 first-degree relatives of thyroid cancer patients from Norway. Cancer Epidemiology, Biomarkers and Prevention. 113-117.
- (2001). Expression of oestrogen and progesterone receptorss, Ki-67, p53 and BCL-2 proteins, cathepsin D, urokinase plasminogen activator and urokinase plasminogen activator-receptors in carcinomas of the female breast in an African poplation. East African Medical Journal. 360-5.
- (1998). Økt forekomst av kreft i skjoldkjertelen blant norske kvinner gift med fiskere. Tidsskrift for Den norske legeforening. 4202-4205.
- (1998). Seasonal variations in the presentation and growth of thyroid cancer. British Journal of Cancer. 1174-1179.
- (1998). Risk of primary childhood brain tumors related to birth characteristics: a Norwegian prospective study. International Journal of Cancer. 498-503.
- (1998). Risk of primary childhood brain tumors related to birth characteristics: a Norwegian prospective study. International Journal of Cancer. 498-503.
- (1998). Prognostic impact of morphometric nuclear grade of endometrial carcinoma. Cancer. 956-964.
- (1998). Prognostic impact of morphometric nuclear grade in endometrial carcinoma. Cancer. 956-964.
- (1998). Poorer survival of nulliparous women with endometrial carcinoma. Cancer. 1328-1333.
- (1998). Independent prognostic importance of microvessel density in endometrial carcinoma. British Journal of Cancer. 1140-1144.
- (1998). Identification of high-risk patients by assessment of nuclear Ki-67 expression in a prospective study of endometrial carcinomas. Clinical Cancer Research. 2779-2785.
- (1998). Frequent mutations of the p53 gene in cutaneous melanoma of the nodular type. International Journal of Cancer. 91-95.
- (1998). Diagnostisk molekylærbiologi ved solide svulster - thyreoidea. Tidsskrift for Den norske legeforening. 2199-2203.
- (1997). Recurrent endometrial carcinoma and the value of routine follow-up. British Journal of Obstetrics and Gynaecology. 1302-1307.
- (1997). Increased risk of thyroid cancer among Norwegian females married to fishery workers. British Journal of Cancer. 385-389.
- (1997). Angiogenesis does not predict clinical response to doxorubicin monotherapy in patients with locally advanced breast cancer. International Journal of Cancer. 138-140.
- (1997). Absence of p21 expression is associated with abnormal p53 in human breast carcinomas. British Journal of Cancer. 480-485.
- (1996). Thyroid carcinomas with tall-cell and columnar-cell features (letter). Current Diagnostic Pathology. 67.
- (1996). Spesific TP53 gene mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nature Medicine. 811-814.
- (1996). Relationship between mutations in the TP53 gene and De Novo resistance and early relapse following treatment with doxorubicin in patients with breast cancer. Nature Medicine. 811-814.
- (1996). Primary systemic treatment with weekly doxorubicin monotherapy in women with locally advanced breast cancer; clinical experience and parameters predicting outcome. Acta Oncologica. 5-8.
- (1996). Primary systemic treatment with weekly doxorubicin monotherapy in women with locally advanced breast cancer; Clinical experience and parameters predicting outcome. Acta Oncologica. 5-8.
- (1996). Primary organ-culture of non neoplastic and neoplastic thyroid tissue as multicellular spheroids. International Journal of Oncology. 1071-1078.
- (1996). Independent prognostic importance of vascular invasion in nodular melanomas. Cancer. 1211-1219.
- (1996). Aggressive thyroid carcinoma with predominant cribriform growth pattern. Pathology, Research and Practice.
- (1995). Histopatologiens betydning for vurdering av kreftforekomst og kreftårsaker. Tidsskrift for Den norske legeforening. 943-946.
- (1994). Ploidy and proliferative rates in carcinomas of the breast in Tanzania. East African Medical Journal. 195-198.
- (1994). Increase of endo-and exo-peptidases in thyroid tumors. Oncol Rep. 953-956.
- (1994). Increase of endo- and exo-peptidases in thyroid tumours. Oncol Rep. 953-956.
- (1994). Etiologiske og patobiologiske aspekter ved malignt melanom. Tidsskrift for Den norske legeforening. 908-911.
- (1993). Thyroid cancer in children in Norway 1953-1987. European Journal of Cancer. 365-366.
- (1993). Prognostic importance of various clinicopathological features in papillary thyroid carcinoma. European Journal of Cancer. 44-51.
- (1993). Prognostic importance of various clinicopathological features in papillary thyroid carcinoma. European Journal of Cancer. 44-51.
- (1993). Prognostic impact of EGF-receptor in papillary thyroid carcinoma. British Journal of Cancer. 808-812.
- (1993). Incidence pattern of thyroid cancer in Norway: influence of birth cohort and time period. International Journal of Cancer. 183-187.
Vitenskapelig foredrag
- (2016). Molecular subtypes of breast cancer: long-term incidence trends and prognostic differences.
- (2016). FGD5 amplification in breast cancer patients is associated with tumour proliferation and a poorer prognosis.
- (2013). Molekylære subtyper og overlevelse ved brystkreft.
- (2013). Molekylære subtyper og overlevelse ved brystkreft.
- (2012). Multimodal imaging for suspected recurrent differentiated thyroid cancer (DTC): FDG-PET-CT, I-131-SPECT-CT, ultrasound (US) and US-guided fine needle biopsy (FNB).
- (2011). Multimodal imaging for diagnosis and treatment of recurrent differentiated thyroid cancer (DTC)FDG-PET-CT, contrast-enhanced CT (CE-CT), I-131-SPECT-CT, ultrasound (US) and US-guided fine needle biopsy (FNB).
- (2011). In vivo Dynamic Contrast Enhanced MRI & Histopathological Assessment of Tumor Angiogenesis in Luminal-like and Basal-like Breast Cancer Xenografts.
- (2011). FDG-PET-CT, I-131-SPECT-CT, ultrasound (US) and US-guided fine needle biopsy (FNB) for recurrent differentiated thyroid cancer (DTC).
- (2011). Early vascular response to bevacizumab treatment measured by DCE-MRI in breast cancer xenografts.
- (2011). DCE-MRI for early therapy monitoring of anti-angiogenic therapy.
- (2010). Real time elastografi ved cancer prostatae.
- (2010). Preliminære resultater av PCA3 måling i urin hos pasienter med cancer prostatae.
- (2010). Multimodal imaging of differentiated thyroid cancer: FDG-PET-CT, I-131-SPECT-CT and ultrasound.
- (2010). In vivo magnetic resonance imaging and histopathological assessment of tumor microenvironment in luminal-like and basal-like breast cancer xenografts.
- (2010). Er preoperativ MR-prostata nyttig for å avklare korrekt T-stadium forut for kirurgi?
- (2010). Er MR-prostata nyttig for å avklare videre oppfølgningsbehov hos pasienter med 2 eller flere negative biopsiserier?
- (2009). Genome-wide profiling of histone H3 lysine 4 and lysine 27 trimethylation reveals an epigenetic signature in prostate carcinogenesis.
- (2009). EMT Promotes Malignant Transformation of Prostate Epithelial Cells in Culture.
- (2008). Polycomb group target genes and bivalent H3K4 & K27me3 modifications in human embryonic cells were enriched among dysregulated genes in prostate cancer.
- (2008). Epithelial to mesenchymal transition of a primary, immortalized prostate cell line is associated with gene expression switches of entire cell attachment modules.
- (2007). Functional oncogenomics and epigenomics analysis of prostate cancer.
- (2007). Detection of TMPRSS2:ERG translocations in the urine of prostate cancer patients and identification of ERG target genes.
- (2006). Global gene expression analysis of transcription factors in prostate cancer and cell lines.
- (2006). ERG upregulation and related transcription factors in prostate cancer.
- (2004). Gene expression profiling in prostate cancer refined by pairwise comparisons of cDNA microarrays from benign and malignant tissue.
- (2004). Gene expression profiles in prostate cancer: identification of upregulated SIM2 gene validated in archival tissue, relation to histological grading and prognosis.
- (2003). Mutation analysis of the RAS-RAF pathway in pancreatic adenocarcinomas and malignant melanomas.
- (2003). Global analysis of gene expression and regulatory patterns in urogenital tumours using DNA microarrays.
- (2003). Global analysis of gene expression and regulatory patterns in cancer.
- (2003). Gene expression profiling in prostate cancer: cluster analysis and association with tumor differentation.
- (2003). Gene expression profiling in prostate cancer: Cluster analysis and association with tumor differentiation.
- (2003). Gene expression profiling in prostate cancer.
- (2003). DNA microarray studies of human cancer - pitfalls and outlook.
- (2003). Comparison of DNA microarray and real time quantitative PCR for quantitation of gene expression of selected genes in prostate cancer.
- (2002). Cancer mammae behandlet med brystbevarende kirurgi ved Haukeland sykehus 1984-1995.
- (2001). Prognostisk betydning av angiogenese (microvessel density - MVD) og proliferasjonsmarkøren Ki-67 ved lokalisert prostatacencer.
- (1999). Prognostic importance of microvessel density (MVD) in clinically localized prostate cancer.
- (1998). Prognostic importance of microvessel density (MVD) in clinically localized prostate cancer.
- (1998). Profylaktisk thyroidectomi hos barn - initial erfaring.
- (1998). Malignt melanom på hender.
- (1998). Malignant melanoma of the hand. A 25-year clinico-pathological study.
- (1997). Independent prognostic importance of microvessel density in endometrial carcinoma. [poster].
- (1989). Mortality form ischemic heart disease related to life-style differences among Norwegian men (Abstract).
Vitenskapelig antologi/Konferanseserie
- (2017). Biomarkers of the Tumor Microenvironment: Basic Studies and Practical Applications. Springer.
Sammendrag/abstract
- (2013). Proliferation markers PHH3, Ki67 and mitotic count all show significant associations with features of aggressive breast carcinomas and reduced survival. Modern Pathology. 50A-50A.
- (2013). Proliferation markers PHH3, Ki67 and Mimtotic count all show significant associations with features of aggressive breast carcinomas and reduced survival. Laboratory Investigation. 50A-50A.
- (2013). FOXA1 LOSS IN ENDOMETRIAL CANCER IS ASSOCIATED WITH POOR PROGNOSIS AND ER ALPHA LOSS. International Journal of Gynecological Cancer. 1 sider.
- (2012). Prognostic impact of proliferation markers Ki-67, PHH3 and mitotic count in breast carcinomas. Virchows Archiv. S5-S5.
- (2012). Metabolic Responses to VEGF Inhibition in Patient-derived Breast Cancer Xenografts. European Journal of Cancer. S32-S32.
- (2012). Expression of hypoxia-inducible factor-1a and associations with vascular endothelial growth factor expression, high microvessel density and features of aggressive tumors in African breast cancer. Virchows Archiv. S249-S249.
- (2012). Estrogen receptor a loss in endometrial carcinoma is associated with epithelial-to-mesenchymal transition and a potential for PI3Kinase inhibition. Virchows Archiv. S18-S18.
- (2011). Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival. Clinical and Experimental Metastasis. 234-235.
- (2010). Prognostic importance of vascular proliferation and tumor cell invasion in blood and lymphatic vessels in endometrial carcinoma. APMIS - Journal of Pathologiy, Microbiology and Immunology. 248-248.
- (2010). Multimodal imaging of differentiated thyroid cancer: FDG-PET-CT, I-131-SPECT-CT and ultrasound [Abstract]. European Journal of Nuclear Medicine and Molecular Imaging. S291-S291.
- (2009). Proliferation of immature tumor vessels is a novel marker of clinical progress in prostate cancer. APMIS - Journal of Pathologiy, Microbiology and Immunology. 233-233.
- (2008). Vascular proliferation by Nestin/Ki-67 is a novel predictor of the clinical progress of prostate cancer. Histopathology. 276-277.
- (2008). Candidate stem cell marker ALDH1 expression and relationship with BRCA-mutations and basal-like differentiation in breast carcinoma. Histopathology. 25-25.
- (2007). Loss of BMI-1 expression is associated with the clinical progress of malignant melanoma. Virchows Archiv. 452-452.
- (2007). Epithelial to mesenchymal transition is of strong prognostic importance in prostate cancer. Virchows Archiv. 344-344.
- (2007). Basal-like phenotype is frequent in invasive breast carcinoma from Ugandan Africans and is strongly associated with a high expression of EGFR/c-Kit and features of aggressive tumors. Virchows Archiv. 137-137.
- (2006). Global gene expression analysis of transcription factors in prostate cancer and cell lines. International Journal of Molecular Medicine. S27.
- (2006). ERG upregulation in relation to other transcription factors in prostate cancer. NBS-nytt. 72.
- (2005). Single-minded 2 homolog gene is overexpressed in prostate cancer. Virchows Archiv. 432-432.
- (2005). Overexpression of ERG and SIM2 transcription factors in prostate cancer. International Journal of Molecular Medicine. S76-S76.
Vitenskapelig oversiktsartikkel/review
- (2013). Malignt melanom – diagnostikk, behandling og oppfølging i Norge. Tidsskrift for Den norske legeforening. 2154-2159.
- (2009). Biologic markers in endometrial cancer treatment. APMIS - Journal of Pathologiy, Microbiology and Immunology. 693-707.
- (2008). Tumor-vascular interactions and tumor dormancy. APMIS - Journal of Pathologiy, Microbiology and Immunology. 569-585.